01 Rapid Scale-up of Ns1/igm Lateral Flow Testing for Outbreak ResponseDuring the 2024–2025 dengue surges, field response relied heavily on rapid NS1 antigen and IgM/IgG combo lateral-flow tests for triage and case detection at primary care and emergency facilities. Vendors such as SD Biosensor and Abbott’s Bioline NS1 launched duo kits that had widespread field use for quick detection within minutes, enabling faster clinical decision-making and surveillance reporting.In April 2025, WHO's interim guidance recommended NS1/antibody rapid diagnostic tests (RDTs) for point-of-care testing in resource-limited and outbreak scenarios, which facilitates faster procurement and funding for these essential rapid diagnostic kits.This created a large, recurring market for low-margin, high-volume rapid tests during epidemics, complemented by lab confirmation spend.
02 Rise of Molecular DiagnosticsMolecular techniques like RT-PCR and loop-mediated isothermal amplification (LAMP) dominate trends by offering high specificity for detecting Zika, chikungunya, and West Nile viruses, with detection limits as low as 10 copies per microliter. These methods enable multiplex testing for co-infections, vital in overlapping endemic zones, reducing false negatives by 30%. Portable devices facilitate use in low-resource settings, with battery-powered units operating in temperatures up to 40°C. AI-enhanced analysis speeds results to under 60 minutes, supporting vaccine trials and surveillance, helping market growth.
01 Government Initiatives and FundingGovernment initiatives are a primary driver for the mosquito-borne infections testing market. As national and international health organisations grapple with rising cases, they are investing in diagnostic capacity to improve surveillance, accelerate response times, and prevent outbreaks.Additionally, WHO and PAHO continue to issue alerts and guidance for dengue in the Americas. These fast-track evaluation and procurement pathways benefit vendors, encouraging investment in testing capacity.
02 Recurrent Dengue Outbreaks and Expanding Geographic RangeEpidemiologic data show that dengue incidence surged in 2024, with over 14 million reported globally as per the WHO. The Americas alone had more than 13 million suspected cases in 2024, driving exceptional testing demand for case management and surveillance.Outbreak-driven demand is large with countries scaling up rapid tests, PCR reagents and lab services rapidly during peaks, producing a significant revenue bump for diagnostics suppliers and recurring replacement demand each season.
01 Cross-Reactivity in Serological TestingA key limitation in mosquito-borne infection diagnostics is the serological cross-reactivity among flaviviruses. For example, antibodies for the dengue virus (IgM/IgG) often react with the Zika virus, the yellow fever virus, or antibodies from previous dengue infections. This overlap reduces the diagnostic specificity of serological tests, especially in regions where multiple flaviviruses circulate or where vaccination campaigns have been conducted. As a result, serological assays alone have limited reliability for case confirmation. Molecular tests (e.g., PCR) are increasingly relied upon for accurate diagnosis and serotyping, but these are more expensive and require well-equipped laboratories.
01 Integrated Point-of-Care (poc) Testing with Digital ReportingPoint-of-care antigen and antibody rapid tests have revolutionised outbreak response by enabling fast, on-site results, crucial for remote areas lacking labs. This model was widely piloted during the 2024–2025 dengue emergencies, with ministries of health and NGOs combining rapid kit distribution with centralised reporting dashboards to map cases and direct vector control resources. Companies like SD Biosensor, with their STANDARD Q dengue kits, have been extensively deployed in Asia and Latin America during this period. These integrated approaches not only generate higher-value revenue streams for suppliers but also encourage long-term procurement contracts from governments and donors.
March 2026 Abbott expanded its infectious disease diagnostics portfolio with advanced testing solutions designed to improve the detection of mosquito-borne infections and support timely clinical decision-making.
September 2025 Roche introduced enhanced molecular diagnostic technologies featuring improved accuracy and faster detection of vector-borne infectious diseases in clinical laboratories.
May 2025 Bio-Rad Laboratories expanded its infectious disease testing portfolio with advanced diagnostic assays focused on improving the detection and monitoring of mosquito-borne pathogens.